Evidence for DNA-binding domain-ligand-binding domain communications in the androgen receptor

Molecular and Cellular Biology

Volumn 32, Issue 15, 2012, Pages 3033-3043

  Helsen, Christine ^a   Dubois, Vanessa ^a   Verfaillie, Annelien ^a   Young, Jacques ^b   Trekels, Mieke ^a   Vancraenenbroeck, Renée ^a   De Maeyer, Marc ^a   Claessens, Frank ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; DNA; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA;

ANDROGEN INSENSITIVITY SYNDROME; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA BINDING DOMAIN; DNA BINDING MOTIF; DNA RESPONSIVE ELEMENT; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; LIGAND BINDING; LIGAND BINDING DOMAIN; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN STRUCTURE;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CRYSTALLIZATION; DNA-BINDING PROTEINS; LIGANDS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN;

EID: 84864622006     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00151-12     Document Type: Article

References (63)

1. Audi L, et al. 2010. Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development. J. Clin. Endocrinol. Metab. 95:1876 -1888.
2. Balk SP, Knudsen KE. 2008. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal. 6:e001. doi:10.1621/nrs.06001.
3. Bevan CL, et al. 1996. Functional analysis of six androgen receptor mutations identified in patients with partial androgen insensitivity syndrome. Hum. Mol. Genet. 5:265-273.
4. Bledsoe RK, et al. 2002. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110:93-105.
5. Boehmer AL, et al. 2001. Genotype versus phenotype in families with androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 86:4151- 4160.
6. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. 1995. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 375:377-382.
7. Buzon V, Carbo LR, Estruch SB, Fletterick RJ, Estebanez-Perpina E. 2012. A conserved surface on the ligand binding domain of nuclear receptors for allosteric control. Mol. Cell. Endocrinol. 348:394-402.
8. Callewaert L, et al. 2003. Implications of a polyglutamine tract in the function of the human androgen receptor. Biochem. Biophys. Res. Commun. 306:46 -52.
9. Callewaert L, Verrijdt G, Christiaens V, Haelens A, Claessens F. 2003. Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements. J. Biol. Chem. 278:8212- 8218.
10. Castagnaro M, Yandell DW, Dockhorn-Dworniczak B, Wolfe HJ, Poremba C. 1993. Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh. Dtsch. Ges. Pathol. 77:119 -123. (In German.)
11. Chandra V, et al. 2008. Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. Nature 456:350 -356.
12. Cheikhelard A, et al. 2008. Long-term followup and comparison between genotype and phenotype in 29 cases of complete androgen insensitivity syndrome. J. Urol. 180:1496 -1501.
13. Choi JH, et al. 2011. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 477:477- 481.
14. Claessens F, et al. 2008. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl. Recept. Signal. 6:e008. doi:10.1621/ nrs.06008.
15. Clinckemalie L, Vanderschueren D, Boonen S, Claessens F. 2012. The hinge region in androgen receptor control. Mol. Cell. Endocrinol. 358: 1-8.
16. Daura X, et al. 1999. Peptide folding: when simulation meets experiment. Angew. Chem. Int. Ed. Engl. 38:236 -240.
17. Delano WL. 2002. The PyMOL molecular graphics system. Delano Scientific, San Carlos, CA.
18. Delhaise P, et al. 1988. The Brugel package-toward computer-aideddesign of macromolecules. J. Mol. Graph. Model. 6:219 -219.
19. Denayer S, Helsen C, Thorrez L, Haelens A, Claessens F. 2010. The rules of DNA recognition by the androgen receptor. Mol. Endocrinol. 24:898- 913.
20. Dominguez C, Boelens R, Bonvin AM. 2003. HADDOCK: a proteinprotein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125:1731-1737.
21. Dubbink HJ, et al. 2004. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol. Endocrinol. 18:2132-2150.
22. Estebanez-Perpina E, et al. 2007. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl. Acad. Sci. U. S. A. 104:16074 -16079.
23. Evans BA, et al. 1996. Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate 28:162-171.
24. Farla P, et al. 2004. The androgen receptor ligand-binding domain stabilizes DNA binding in living cells. J. Struct. Biol. 147:50-61.
25. Ferlin A, et al. 2006. Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations. Clin. Endocrinol. (Oxf.) 65:606-610.
26. Ghali SA, et al. 2003. The use of androgen receptor amino/carboxylterminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity. J. Clin. Endocrinol. Metab. 88:2185-2193.
27. Haelens A, et al. 2001. Androgen-receptor-specific DNA binding to an element in the first exon of the human secretory component gene. Biochem. J. 353:611- 620.
28. Hannema SE, et al. 2004. Residual activity of mutant androgen receptors explains Wolffian duct development in the complete androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 89:5815-5822.
29. He B, Kemppainen JA, Wilson EM. 2000. FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275:22986 -22994.
30. He B, Minges JT, Lee LW, Wilson EM. 2002. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J. Biol. Chem. 277:10226 -10235.
31. Helsen C, et al. Structural basis for nuclear hormone receptor DNA binding. Mol. Cell. Endocrinol. 348:411- 417.
32. Hiort O, et al. 2000. Significance of mutations in the androgen receptor gene in males with idiopathic infertility. J. Clin. Endocrinol. Metab. 85: 2810-2815.
33. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K. 1996. The clinical and molecular spectrum of androgen insensitivity syndromes. Am. J. Med. Genet. 63:218 -222.
34. Hiort O, Sinnecker GH, Holterhus PM, Nitsche EM, Kruse K. 1998. Inherited and de novo androgen receptor gene mutations: investigation of single-case families. J. Pediatr. 132:939 -943.
35. Idkowiak J, et al. 2010. Concomitant mutations in the P450 oxidoreductase and androgen receptor genes presenting with 46,XY disordered sex development and androgenization at adrenarche. J. Clin. Endocrinol. Metab. 95:3418 -3427.
36. Jaaskelainen J, et al. 2006. Human androgen receptor gene ligandbinding-domain mutations leading to disrupted interaction between the N- and C-terminal domains. J. Mol. Endocrinol. 36:361-368.
37. Jeske YW, et al. 2007. Androgen receptor genotyping in a large Australasian cohort with androgen insensitivity syndrome; identification of four novel mutations. J. Pediatr. Endocrinol. Metab. 20:893-908.
38. Kalkhoven E, Valentine JE, Heery DM, Parker MG. 1998. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor. EMBO J. 17:232-243.
39. The Lady Davis Institute for Medical Research. 2012. Androgen Receptor Gene Mutation Database. The Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec, Canada. http://androgendb .mcgill.ca/.
40. Luisi BF, et al. 1991. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352:497-505.
41. Marcelli M, et al. 1991. A mutation in the DNA-binding domain of the androgen receptor gene causes complete testicular feminization in a patient with receptor-positive androgen resistance. J. Clin. Invest. 87:1123- 1126.
42. Matias PM, et al. 2000. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 275:26164 -26171.
43. Meijsing SH, Elbi C, Luecke HF, Hager GL, Yamamoto KR. 2007. The ligand binding domain controls glucocorticoid receptor dynamics independent of ligand release. Mol. Cell. Biol. 27:2442-2451.
44. Meijsing SH, et al. 2009. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324:407- 410.
45. Nemoto T, Ohara-Nemoto Y, Shimazaki S, Ota M. 1994. Dimerization characteristics of the DNA- and steroid-binding domains of the androgen receptor. J. Steroid Biochem. Mol. Biol. 50:225-233.
46. Orlov I, Rochel N, Moras D, Klaholz BP. 2012. Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. EMBO J. 31:291-300.
47. Putcha BD, Fernandez EJ. 2009. Direct interdomain interactions can mediate allosterism in the thyroid receptor. J. Biol. Chem. 284:22517-22524.
48. Ris-Stalpers C, et al. 1991. Substitution of aspartic acid-686 by histidine or asparagine in the human androgen receptor leads to a functionally inactive protein with altered hormone-binding characteristics. Mol. Endocrinol. 5:1562-1569.
49. Rochel N, et al. 2011. Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. Nat. Struct. Mol. Biol. 18:564 -570.
50. Schaufele F, et al. 2005. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc. Natl. Acad. Sci. U. S. A. 102:9802-9807.
51. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. 2004. Structural basis of androgen receptor binding to selective androgen response elements. Proc. Natl. Acad. Sci. U. S. A. 101:4758-4763.
52. Shiau AK, et al. 1998. The structural basis of estrogen receptor/ coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.
53. Shkolny DL, et al. 1999. Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively. J. Clin. Endocrinol. Metab. 84:805- 810.
54. Tadokoro R, Bunch T, Schwabe JW, Hughes IA, Murphy JC. 2009. Comparison of the molecular consequences of different mutations at residue 754 and 690 of the androgen receptor (AR) and androgen insensitivity syndrome (AIS) phenotype. Clin. Endocrinol. (Oxf.) 71:253-260.
55. Tanenbaum DM, Wang Y, Williams SP, Sigler PB. 1998. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. U. S. A. 95:5998-6003.
56. Van de Wijngaart DJ, Dubbink HJ, Van Royen ME, Trapman J, Jenster G. 2012. Androgen receptor coregulators: recruitment via the coactivator binding groove. Mol. Cell. Endocrinol. 352:57-69.
57. Van Royen ME, et al. 2007. Compartmentalization of androgen receptor protein-protein interactions in living cells. J. Cell Biol. 177:63-72.
58. Van Tilborg MA, et al. 2000. Mutations in the glucocorticoid receptor DNA-binding domain mimic an allosteric effect of DNA. J. Mol. Biol. 301:947-958.
59. Wang Q, et al. 1998. Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation. J. Clin. Endocrinol. Metab. 83: 4303-4309.
60. Wurtz JM, et al. 1996. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3:87-94.
61. Yong EL, Tut TG, Ghadessy FJ, Prins G, Ratnam SS. 1998. Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain. Mol. Cell. Endocrinol. 137:41-50.
62. Zhang J, et al. 2011. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat. Struct. Mol. Biol. 18:556 -563.
63. Zoppi S, et al. 1992. Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptorbinding positive androgen resistance. Mol. Endocrinol. 6:409-415